• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮肤科患者需求维度:患者获益指数的子量表。

Dimensions of patient needs in dermatology: subscales of the patient benefit index.

机构信息

CVderm-German Center for Health Services Research in Dermatology, Institute for Health Services Research in Dermatology, University Clinics of Hamburg, Germany.

出版信息

Arch Dermatol Res. 2011 Jan;303(1):11-7. doi: 10.1007/s00403-010-1073-0. Epub 2010 Aug 17.

DOI:10.1007/s00403-010-1073-0
PMID:20714739
Abstract

Evaluation of patient-relevant treatment benefit gains importance for approval and reimbursement of therapeutic strategies. The 'Patient Benefit Index' (PBI) is the first questionnaire to measure patient-relevant treatment benefit in dermatology. Its global score is the average of benefits achieved after treatment, weighted by the individual importance of treatment needs. This study aimed to establish subscales of the PBI on the basis of independent and consistent treatment need dimensions. The PBI was used in a cross-sectional study involving n = 500 patients with ten distinct skin diseases, and in a longitudinal acne therapy study (n = 925). PBI dimensions were extracted by factor analysis and varimax rotation in both studies independently, using the longitudinal study data for replication. Factor analysis revealed largely similar need dimensions in both studies. The five-dimensional solution found in the cross-sectional study explained 63.0% of the variance. The need dimensions were named as reducing psychological impairments, reducing social impairments, reducing impairments due to therapy, reducing physical impairments, and building confidence into therapy. Using this factor solution, different patterns of need were found amongst the ten dermatological diseases. The PBI allows for a differential benefit assessment on five well distinguishable and interpretable subscales. The use of subscales as shown refines the interpretation of needs and benefits in dermatologic treatment.

摘要

评估与患者相关的治疗获益对于治疗策略的批准和报销变得越来越重要。“患者获益指数”(PBI)是第一个用于衡量皮肤科患者相关治疗获益的问卷。它的总体评分是治疗后获得的获益的平均值,权重为治疗需求的个体重要性。本研究旨在基于独立且一致的治疗需求维度,为 PBI 建立子量表。该 PBI 用于一项涉及 500 名十种不同皮肤病患者的横断面研究,以及一项涉及 925 名痤疮治疗患者的纵向研究。在两项研究中,均使用纵向研究数据进行复制,通过因子分析和方差极大旋转从 PBI 中提取维度。因子分析显示,两项研究中的需求维度基本相似。横断面研究中的五维度解决方案解释了 63.0%的方差。需求维度分别命名为减少心理障碍、减少社交障碍、减少治疗相关障碍、减少身体障碍和增加对治疗的信心。使用该因子解决方案,在十种皮肤病中发现了不同的需求模式。PBI 允许在五个易于区分和解释的子量表上进行差异化的获益评估。子量表的使用如文中所示,可以细化皮肤科治疗中需求和获益的解释。

相似文献

1
Dimensions of patient needs in dermatology: subscales of the patient benefit index.皮肤科患者需求维度:患者获益指数的子量表。
Arch Dermatol Res. 2011 Jan;303(1):11-7. doi: 10.1007/s00403-010-1073-0. Epub 2010 Aug 17.
2
The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases.患者获益指数:皮肤病患者定义结局测量的一种新方法。
Arch Dermatol Res. 2009 Sep;301(8):561-71. doi: 10.1007/s00403-009-0928-8. Epub 2009 Mar 27.
3
Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.验证患者获益指数在评估银屑病治疗中患者相关获益的应用。
Arch Dermatol Res. 2012 Aug;304(6):433-41. doi: 10.1007/s00403-012-1256-y. Epub 2012 Jun 22.
4
Measurement of patient-relevant benefits in the treatment of chronic hand eczema--a novel approach.慢性手部湿疹治疗中与患者相关益处的测量——一种新方法。
Contact Dermatitis. 2009 Jul;61(1):39-45. doi: 10.1111/j.1600-0536.2009.01536.x.
5
Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool.测量瘙痒治疗中的患者相关获益:特定结局工具的开发和验证。
Br J Dermatol. 2009 Nov;161(5):1143-8. doi: 10.1111/j.1365-2133.2009.09328.x.
6
Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".患者获益指数(PBI)在银屑病治疗中的应用——“PsoHealth”国家护理研究结果。
Eur J Dermatol. 2013 Apr 1;23(2):212-7. doi: 10.1684/ejd.2013.1988.
7
Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool.评估淋巴水肿和脂肪水肿治疗的患者相关结局:一种新获益工具的开发和验证。
Eur J Vasc Endovasc Surg. 2014 Jan;47(1):100-7. doi: 10.1016/j.ejvs.2013.10.009. Epub 2013 Oct 22.
8
Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit.评估支持性皮肤护理的价值:一种评估患者相关益处的工具的开发与验证
Dermatology. 2009;218(3):255-9. doi: 10.1159/000195174. Epub 2009 Jan 21.
9
Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne.一种用于评估痤疮治疗中患者定义获益的新工具的开发与验证
J Dtsch Dermatol Ges. 2008 Feb;6(2):113-20. doi: 10.1111/j.1610-0387.2007.06540.x. Epub 2007 Nov 9.
10
Development of a multidimensional measure for recurrent abdominal pain in children: population-based studies in three settings.儿童复发性腹痛多维测量方法的开发:在三种环境下开展的基于人群的研究
Pediatrics. 2005 Feb;115(2):e210-5. doi: 10.1542/peds.2004-1412.

引用本文的文献

1
Patient needs in women of childbearing age with psoriasis: retrospective analysis from the German PsoBest registry.育龄期银屑病女性患者的需求:来自德国PsoBest注册研究的回顾性分析
Int J Womens Dermatol. 2024 Sep 11;10(3):e176. doi: 10.1097/JW9.0000000000000176. eCollection 2024 Oct.
2
Development of a Specific Variant of Patient Benefit Index (PBI) Assessing Patient Needs, Goals and Benefits in Rosacea Treatment.开发一种特定变体的患者获益指数(PBI),用于评估酒渣鼻治疗中的患者需求、目标和获益。
Patient Prefer Adherence. 2023 Jun 1;17:1335-1345. doi: 10.2147/PPA.S378724. eCollection 2023.
3
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
基于真实世界数据使用特诺雅治疗患者的报告健康状况:一项多国、四期、单队列前瞻性观察研究(POSITIVE 研究)方案。
BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536.
4
Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.识别大疱性表皮松解症患者的需求和感知到的治疗益处:一项使用患者获益指数的探索性研究。
J Clin Med. 2021 Dec 13;10(24):5836. doi: 10.3390/jcm10245836.
5
[Regional variations in healthcare for patients with psoriasis and atopic dermatitis in Germany].[德国银屑病和特应性皮炎患者医疗保健的地区差异]
Hautarzt. 2022 Jan;73(1):27-39. doi: 10.1007/s00105-021-04913-2. Epub 2021 Nov 25.
6
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.来自BREEZE-AD7 3期随机试验的结果:巴瑞替尼联合外用糖皮质激素对中度至重度特应性皮炎成年患者的特应性皮炎症状、生活质量及功能的影响
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):1543-1552. doi: 10.1111/jdv.17278. Epub 2021 Jun 5.
7
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab.使用阿达木单抗、依那西普或乌司奴单抗治疗后疾病活动度低的银屑病患者未满足的个人患者需求
Drugs Real World Outcomes. 2021 Jun;8(2):163-172. doi: 10.1007/s40801-021-00227-w. Epub 2021 Mar 28.
8
Documenting Patient Data in Psoriasis Clinical Practice-Patient Focus Groups Supporting Psoriasis Experts' Decision-making.在银屑病临床实践中记录患者数据——支持银屑病专家决策的患者焦点小组
Patient Prefer Adherence. 2021 Mar 8;15:549-557. doi: 10.2147/PPA.S297569. eCollection 2021.
9
Identifying and appraising patient-reported outcome measures on treatment satisfaction in acne: a systematic review.识别和评价痤疮治疗满意度的患者报告结局测量指标:系统评价。
Br J Dermatol. 2021 Jul;185(1):36-51. doi: 10.1111/bjd.19675. Epub 2020 Dec 28.
10
Management of chronic pruritus: from the dermatological office to the specialized itch center: a review.慢性瘙痒的管理:从皮肤科诊所到专业瘙痒中心:综述
Itch (Phila). 2017 Sep;2(2):e6. doi: 10.1097/itx.0000000000000006. Epub 2017 Oct 2.